Once-yearly Aclasta® recommended in EU to treat male osteoporosis and reduce risk of new fractures in patients after hip fracture

in

  • Male indication important as osteoporosis often neglected in men - estimated one in five men aged over 50 may suffer an osteoporosis-related fracture[1]


  • Positive opinion also expands once-yearly Aclasta indication to include osteoporosis patients who recently suffered a low-trauma hip fracture
  • EU label to include data showing 35% reduction in new fractures and 28% reduction of all-cause mortality[2] in post-hip fracture patients treated with Aclasta
  • Recommendation comes shortly after similar change to US label for Reclast[3][*]